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Abstract
Background: Chronic kidney disease (CKD) is a global public health problem. Currently, as for advanced CKD
populations, medication options limited in angiotensin-converting enzyme inhibitors (ACEi) and angiotensin
receptor blockers (ARB), which were partially effective. A Chinese herbal compound, Bupi Yishen formula, has
showed renal protective potential in experiments and retrospective studies. This study will evaluate the efficacy
and safety of Bupi Yishen formula (BYF) in patients with CKD stage 4.
Design: In this double blind, double dummy, randomized controlled trial (RCT), there will be 554 non-diabetes
stage 4 CKD patients from 16 hospitals included and randomized into two groups: Chinese medicine (CM) group or
losartan group. All patients will receive basic conventional therapy. Patients in CM group will be treated with BYF
daily while patients in control group will receive losartan 100 mg daily for one year. The primary outcome is the
change in estimated glomerular filtration rate (eGFR) over 12 months. Secondary outcomes include the incidence
of endpoint events, liver and kidney function, urinary protein creatinine ratio, cardiovascular function and quality
of life.
Discussion: This study will be the first multi-center, double blind RCT to assess whether BYF, compared with
losartan, will have beneficial effects on eGFR for non-diabetes stage 4 CKD patients. The results will help to
provide evidence-based recommendations for clinicians.
Trial registration: Chinese Clinical Trial Registry Number: ChiCTR-TRC-10001518.
* Correspondence: wenzh@gzucm.edu.cn; xushengliu801@126.com
2Key Unit of Methodology in Clinical Research, Guangdong Provincial
Hospital of Chinese Medicine, Guangzhou 510120, China
1Nephrology Center, Guangdong Provincial Hospital of Chinese Medicine,
Guangzhou 510120, China
Full list of author information is available at the end of the article
© 2015 Mao et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mao et al. BMC Complementary and Alternative Medicine  (2015) 15:316 
DOI 10.1186/s12906-015-0830-1
Background
The high incidence of chronic kidney disease (CKD) and
associated poor outcomes presents a major public health
problem in many developed countries. The prevalence
of CKD ranges from 9.4 to 13.0 % in China [1, 2], which
is similar to the reported prevalence in North America
[3, 4] and Australia [5].
Patients with CKD are at a high risk of cardiovascular
events and can gradually develop end stage renal disease
(ESRD), with a decreasing estimated glomerular filtra-
tion rate (eGFR) of 2 to 20 ml/min/1.73 m2 per year [6].
Patients with ESRD require renal replacement therapy to
maintain their life, and the rising prevalence of CKD
represents an increasing economic burden to many
countries. For example, in Taiwan, only 7.7 % of those
over the age of 65 are diagnosed with CKD, but 15.9 %
of the national health care expenditure is spent treating
this condition [7].
The current treatments applied to delay the progres-
sion of CKD are limited and only partially effective.
Angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARBs) are recommended
for their antihypertensive and proteinuria-reducing ef-
fects [5]. However, ACEi or ARBs can only reduce
the risk of ESRD by 50 % [8]. The risks of adverse
events including hyperkalemia and acute kidney injury
limit the application of ACEi/ARBs in advanced CKD
(stages 4 and 5) and elderly patients [9]. Aside from
ACEi/ARB and complication management, there are
no effective treatments for advanced CKD [5]. Thus,
a novel, economical and effective intervention is ur-
gently sought.
In China, Chinese medicine (CM) is widely applied for
CKD and an evidence-base application of CM is gradually
accumulating. Several large clinical studies have indicated
benefit effects of Chinese herbal medicine in early stage
CKD patients [10, 11]. However, CM interventions for
stage 4 CKD populations are lacking, and further investi-
gations are required to evaluate the risks and benefits of
CM in this subgroup population.
Bupi Yishen formula (BYF), a Chinese herbal com-
pound, was developed from the classical Chinese pre-
scription Sijunzi decoction, and was modified according
to data mining 10,000 CKD stage 4 outpatient records.
BYF exhibited a potential renal protective effect in pre-
liminary unpublished observational studies. Twenty-six
CKD stage 4 patients were treated with BYF orally once
a day based on conventional western therapy. After
one-year, eGFR decline was observed in 17 of 26 pa-
tients, with a mean reduction of 2.39 (mean: 2.39,
standard deviation: 5.59). The decline of eGFR was
slower than 6.8 ml/min/1.73 m2 per year receiving bena-
zepril in patients with CKD stage 4 that observed in Hou’s
study [12].
Components of BYF include Astragalus mongholicus
(Huangqi), Codonopsis pilosula (Dangshen), Macrocephalae
(Baizhu), Poria cocos (Fuling), Rhizoma dioscoreae
(Shanyao), Semen coici (Yiyiren), Radix polygoni mul-
tiflori (Heshouwu), Semen cuscutae (Tusizi), and Salvia
miltiorrhiza (Danshen). Some of these components
have been reported to reduce proteinuria, inhibit renal
fibrosis and improve renal function in experimental
studies [13–16]. Based on this evidence, a trial was de-
signed to assess the efficacy and safety of BYF for delaying
progression in patients with non-diabetes stage 4 CKD.




This multi-center, double blind, double dummy, random-
ized controlled trial (RCT) will be conducted in China
(see Fig. 1). Approximately 554 patients will be divided
into the CM group or losartan group at a 1:1 ratio.
Ethics approval and registry
The study will be conducted in accordance with the
Declaration of Helsinki, and was approved by the Ethics
Committee of Guangdong Provincial Hospital of Chinese
Medicine (No. B2010-11-03). The study was registered at
the Chinese Clinical Trial Registry (No. ChiCTR-TRC-
10001518). Written informed consent will be obtained
from each eligible patient.
Settings
The study will be organized by the Guangdong Provincial
Hospital of Chinese Medicine and conducted at 16 centers
identified as tertiary level TCM hospitals from different
provinces in China.
Participants
All patients diagnosed with stage 4 CKD and CM
syndrome-spleen and kidney qi deficiency (SKQD) will
be recruited. Stage 4 CKD is defined as a severe reduction
in eGFR of 15–29.9 ml/min/1.73 m2 for at least 3 months
[17]. SKQD is a CM diagnose based on clinical symptoms,
signs, tongue appearance and pulse [18, 19], and was con-
firmed by two senior physicians.
Inclusion and exclusion criteria
The participant inclusion criteria are as follows: age
from 18 to 80 years; diagnosed with stage 4 CKD at least
3 months prior to enrollment; blood pressure below
140/90 mmHg.
The participant exclusion criteria are as follows:
imminent initiation of renal replacement therapy; current
corticosteroid or immunosuppressive therapy; serious
arrhythmia, heart failure (New York Heart Association
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Functional Classification stage 4), myocardial infarction,
unstable angina, or cerebrovascular accident; concomitant
diabetes, malignant tumor, hepatitis B, decompensating
liver cirrhosis, active tuberculosis, acute infectious disease
contributing to CKD progression, or any condition (men-
tal or physical) that would interfere with participants’ abil-
ity to comply with the study protocol; GFR fluctuated by
more than 30 % within the 3 months prior to enrollment;
hyperkalemia (serum potassium level higher than the
upper reference interval limit); history of allergy to any
component of the interventions; pregnant or lactating; en-
rolled in another clinical trial.
Randomization
Eligible participants will be assigned to each group using
blocked randomization, stratified by the participating
centers, with a 1:1 allocation ratio using a confidential
block size.
Randomization will be performed by the Key Unit of
Methodology in Clinical Research (KUMCR) of the
Guangdong Provincial Hospital of Chinese Medicine. A
computer-generated randomization list created from
PROC PLAN in SAS 9.2 (SAS Institute, Cary, NC, USA)
will be used. Randomization instructions and blinding
codes will be delivered to each participating site via the
Fig. 1 Clinical trial flow diagram
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Interactive Web Response System for Chinese Medicine
Trials (IWRS-CMT), a validated web-based randomization
system. Each patient will receive a treatment blinding code
and all processes will be recorded and saved.
Blinding
Patients, investigators, monitoring members, outcome
assessors, and statisticians will be blinded to group as-
signment and intervention. The randomization list and
blinding codes will remain confidential, and only the
KUMCR staff will have access to the randomization
list. Blinding will be ensured using the double-dummy
method.
Intervention
Enrollment will be followed by a 3-week run-in period,
and then patients will receive BYF plus losartan-
matched placebo (CM group) or losartan plus BYF-
matched placebo (losartan group) for one year. Patients
with unstable BP within the six weeks prior to enroll-
ment that are taking ACEi/ARBs, will be administered
other types of antihypertensive agents to reduce BP
below 140/90 mmHg.
All Chinese herbs will be obtained from Guangdong
Kangmei Pharmaceutical Co. (Guangzhou, Guangdong,
China). All herbs will be authenticated by macroscopic
and microscopic examination of cross sections, chemical
tests and chromatographic analysis. To ensure these
herbs are safe for human consumption the agricultural
residue screening test for heavy metals, pesticides, and
aflatoxins will be performed.
The BYF herbs will be extracted with hot water, then
concentrated, spray-dried, and packed in sealed opaque
sachets. The entire manufacturing process will comply
with Chinese GMP. Sandoz Corp. Ltd. (Zhongshan city,
Guangdong, China) will produce the losartan tablet pla-
cebos with an identical appearance, smell and taste,
packed in exactly the same way.
In the BYF group, patients will be instructed to dis-
solve a BYF sachet in 150 ml of boiled water and to take
this solution orally three times daily and a losartan-
matched placebo daily for 1 year. Patients in the losartan
group will be instructed to take 100 mg losartan orally
once daily and also a placebo sachet dissolved in 150 ml
of boiled water three times daily for 1 year.
Concurrent CKD-related management
All participants will also receive conventional CKD man-
agement, including dietary therapy, blood pressure con-
trol, management of anemia, regulation of fluid and
acid–base disorders, etc., without limitation of dialysis
or transplant planning according to the Clinical Practice
Guideline [17].
During the intervention period, patients will be ad-
vised not to take any other ACEi/ARB or other Chinese
medicines with a similar function as the BYF or com-
pound α-ketoacid tablets, and if they do so these pa-
tients will be excluded.
Outcome measurements
Primary outcome
The primary outcome is the change in eGFR over
12 months. Decline of eGFR has been widely applied as
primary outcome in several trials, such as the Hyper-
tension (AASK) [20], MDRD Study [21] and the
Ramipril in Non-diabetic Renal Failure Study (REIN)
[22]. The eGFR will be calculated by the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration)
formula [23], and evaluated at baseline, and after 3, 6,
9 and 12 months of the follow-up period.
Secondary outcomes
The secondary outcomes include urinary protein creatin-
ine ratio, serum creatinine level, biochemical test, car-
diovascular function, quality of life and endpoint events
(Table 1).
The urinary protein creatinine ratio will be examined
at baseline, and at 3, 6, 9 and 12 months. Serum creatin-
ine level (SCr) and blood urea nitrogen level (BUN) will
be measured at baseline, and at 1, 2, 3, 6, 9, and
12 months. Biochemical tests including plasma albumin,
triglyceride, cholesterol, calcium, phosphate, and intact
parathyroid hormone level (iPTH) will be measured at
baseline, and at 3, 6, 9, and 12 months.
We will assess the patient's cardiovascular function by
left ventricular ejection fraction (LVEF), interventricular
septal thickness (IVST), left ventricular posterior wall
thickness (LVPWT), carotid artery intima-media thickness
(CIMT) through the Carotid Doppler and Cardiac Dop-
pler, which will be measured at baseline and 12 months.
The Kidney Disease Quality of Life Instrument
(KDQOLSF 1.3) scale will be evaluated at baseline and
at 6 and 12 months.
Endpoint events are defined as serum creatinine level
increasing to double the baseline level, ESRD (requiring
permanent dialysis or kidney transplantation), cardiovas-
cular or cerebrovascular events (acute myocardial infarc-
tion, heart failure, ischemic cerebral infarction or cerebral
hemorrhage verified by typical clinical manifestations,
electrocardiogram (ECG) alterations, and imaging and la-
boratory investigations) or death. The nature and severity
of events will be recorded as endpoint events during the
follow-up period.
Safety evaluation
Participants will be asked to report all adverse events
(AEs) at each follow up. AEs are defined as any symptom
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Table 1 Schedule of study
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occurring during the intervention period [24]. Expected
AEs include dizziness, diarrhea and thirst. Where AEs are
reported, clinicians will provide the appropriate treatment
in accordance with the study standard operative proce-
dures (SOPs). Laboratory examinations, including routine
blood test, urine and stool tests, serum potassium, liver
function (AST, ALT), will be monitored at baseline, 3, 6, 9
and 12 months. Serum potassium concentration will be
closely monitored at each month. ECG will be reviewed
every six month. All AEs will be classified by investigator
based on treatment, involving system, severity and tem-
poral correlation with interventions.
Any serious adverse events (SAEs) will be reported, re-
corded and treated within 24 hours, and reported to the
principle investigator and ethics committee for causality
assessment. The causality assessment for AEs will be
performed according to the WHO-UMC standard [25].
Sample size calculation
The sample size calculation will be based upon a retro-
spective analysis of the change in eGFR in patients with
stage 4 CKD treated at our hospital between 2003 to
2010, and Hou’s trial published in 2006 [12]. Our retro-
spective analysis indicated that the mean eGFR decrease
was 4.5 ± 4.2 ml/min/1.73 m2 per year in patients with
stage 4 CKD treated with CM. Hou’s trial reported that
the median rate of GFR decrease was around 6.8 ml/
min/1.73 m2 per year in patients with stage 4 CKD re-
ceiving benazepril [12]. PASS 2008 software (NCSS,
LLC, Kaysville, Utah, USA) was used to calculate the
sample size required for the current study to allow a su-
periority test to be performed for the BYF group versus
the losartan group where 1 ml/min/1.73 m2 GFR is con-
sidered to indicate a clinically important difference with
a 90 % power and a one-tailed significance level of 2.5 %.
The study was calculated to require 221 patients per
group. Predicting a 20 % lost to follow-up rate, we ad-
justed the total sample size to 277 for each group.
Statistical analyses
An independent team of data managers and statisticians
from KUMCR, will be responsible for the data manage-
ment and statistical analysis of this study. The statisti-
cians will be blinded to the randomized allocation of
groups. PAWS 18.0 (IBM SPSS Inc., Armonk, New York,
USA) and SAS 9.2 (SAS Institute Inc., Cary, USA) statis-
tical software packages will be used to analyze the data.
Prior to analyses, the statistical analysis plan will be
written, updated and confirmed after blind data review.
The full analysis population is defined as patients ran-
domized to receive at least one treatment dose, with
baseline and at least one post-baseline efficacy assess-
ment. The per-protocol population is defined as patients
who complete the course of the study without a major
protocol violation. The primary outcome analysis is based
on full analysis population, intention-to-treat principle
and the per protocol population. An intention-to-treat
analysis will be applied using the imputation method for
missing data. The linear trend at point method will be
used to replace missing values. The existing series will be
regressed on an index variable scaled 1 to n, and the miss-
ing values will be replaced with their predicted values. If
the predicted values cannot be computed, the last obser-
vation carried forward (LOCF) method will be used for
this variable. For analysis of endpoint events, a mixed
effect model will also be employed, adjusting for co-
variables including baseline characteristics. After reporting
descriptive statistics of baseline characteristics for each
group, an effectiveness analysis will compare the BYF and
losartan groups, and a superiority test, with a 95 % confi-
dence interval for eGFR, will be performed to investigate
the clinical difference associated with BYF.
The eGFR will be analyzed using a mixed effect GLM
with terms for treatment, time point, center, and some
baseline characteristics as co-variables based on the con-
cept of repeated measure analysis or adjusted nominal
significance level. The Mann–Whitney U-test will be
used to analyze ordinal categorical variables. An analysis
of variance (ANOVA) will be used for numerical vari-
ables, and a Chi-square test or Fisher exact test will be
used for categorical variables.
An analysis of covariance will be used for continuous
variables, and the Cochran–Mantel–Haenszel test will
be used for categorical variables to adjust for the center
effect. Unconditional logistic regression analysis will be
used for the curative effect factors analysis. The Kaplan–
Meier method will be used to assess the incidence and
mean occurrence time of endpoint events. Cox propor-
tional hazards regression will be used to analyze factors
influencing the incidence of endpoint events. Subgroup
analysis of risk factors including hypertension, protein-
uria will be performed. The Fisher exact test will be used
to compare the incidence rates of AEs and adverse drug
reactions over the course of treatment.
Termination and withdrawal
Patients failing to complete the clinical observation will
be classified as case dropouts. Investigators will contact
these patients and attempt to record the reason for
dropping out and the last time they took the studied
medicine. Participants will be withdrawal from the study
in any of the following situations: 1) commencing per-
manent renal replacement therapy (dialysis >30 days or
kidney transplantation); 2) severe infection, hyperkale-
mia (K+ > 6.5 mmol/L), acidosis (TCO2 < 13 mmol/L), or
heart failure not curable by medication, deterioration of
kidney function that demands dialysis, massive hemorrhage
of the gastrointestinal tract, serious arrhythmia dependent
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on anti-arrhythmic drugs, or uremic encephalopathy; 3)
severe primary disease such as an active-stage malignant
tumor, decompensating liver cirrhosis, or hematopoietic
system disease; 4) urinary tract obstruction that re-
quires surgical treatment; 5) death; 6) withdrawal of
consent; 7) transfer to a renal unit which is not an
active study site.
Quality control and compliance improvement
This trial will be monitored by contract research orga-
nization program managers from, Guangdong International
Clinical Research Center of Chinese Medicine (Guangzhou,
China), contracted by the research sponsor. The program
manager and their team will visit each site to examine trial
procedures, ensure data quality, and monitor compliance
with the protocol. A data safety monitoring board, consist-
ing of seven independent members, will be established to
assess safety events, primary outcomes, and data quality.
The department of science research of Guangdong Pro-
vincial Hospital of Chinese Medicine will be responsible
for trial auditing and inspection for the study.
Measurement of eGFR will be delivered in accordance
with the protocol. The investigators will attend a 3-hour
training workshop on the protocol and will be provided
with a protocol and relevant SOPs. The detection of SCr
used to estimate eGFR will be standardized at all sites.
All sites will be requested to use the same method, pro-
cedure, and reagent when performing SCr detection.
The precision performance of SCr will be evaluated using
the guidelines in the CLSI Document EP15-A2
published in 2005 by American Clinical and Labora-
tory Standards Institution (CLSI) [26]. The laboratory
method of SCr concentration detection at each site will be
validated with a standard substance and will only be
accepted if the SCr coefficient of variation is between
1.0 % and 3.0 %.
Discussion
This multi-center, double blind RCT in stage 4 CKD
patients aims to assess the capacity of a Chinese
herbal formula BYF to reduce progression of stage 4
CKD. Design of this trial complies with the good clin-
ical practice (GCP) guidelines for evaluating efficacy
and safety.
In China, herbal formulas processed by water boiling,
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Chart 1 Underlying Multi-compound, multi-target, multi-pathway network of Bupi Yishen formula in retarding progression of chronic
kidney disease








Radix Polygoni Multiflor 3
Semen coici 4
Salvia miltiorrhiza 3
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of years. These formulas usually consist of several different
herbs formulated based on CM theory. Chinese herbal
medicine has also been applied specifically to CKD pa-
tients for years. The BYF originated from one of the most
famous Chinese prescriptions Sijunzi decoction, and was
modified by senior CM practitioners according to the re-
sults of data mining 10,000 CKD stage 4 patients’ medical
records. This formula, consisting of nine herbs, has been
reported to exert a protective effect in CKD. In this
formula, Astragalus mongholicus (Huangqi), Codonopsis
pilosula (Dangshen), Macrocephalae (Baizhu), Poria cocos
(Fuling), Rhizoma dioscoreae (Shanyao) may regulate
immune functions, improve nutrient status and re-
duce the incidence of infection [27–31]. Astragalus
mongholicus (Huangqi), Salvia miltiorrhiza (Danshen)
and Semen coici (Yiyiren) may exert a anti-fibrotic ef-
fect [32–34] while Codonopsis pilosula (Dangshen),
Semen cuscutae (Tusizi), Radix polygoni multiflori
(Heshouwu), Salvia miltiorrhiza (Danshen) may reduce
oxidative stress [35–38]. The underling mechanism and
ratio of each component of Bupi Yishen Formula are
shown in Chart 1 and Table 2.
Fig. 2 Ultra-performance liquid chromatography-mass spectrometry pattern of Bupi Yishen formula
Fig. 3 Mass spectra of Bupi Yishen formula (ultraviolet; positive ion mode; negative ion mode)
Mao et al. BMC Complementary and Alternative Medicine  (2015) 15:316 Page 8 of 10
The chemical content of BYF was assessed by Ultra-
performance liquid chromatography-mass spectrometry
(LC-MS), and the five major chemical components were
found to be Salvianolic acid B, Calycosin, Cuscutic acid
C, glycerin trioleate and Astragaloside I (Figs. 2 and 3).
In 2014, the BYF formula and the methods of producing
it were approved and patented as a treatment for CKD
by the Chinese State Intellectual Property Office (NO.
2012100298628).
In this trial, the efficacy of BYF will be compared to
losartan. In CKD, patients’ GFR diminishes, and the risk
of cardiovascular disease increases. ACEI/ARBs are known
to exert both renal and cardiac protective effects. Recently,
the ROAD study confirmed the benefit of ARB in stage 4
CKD [8]. Therefore, it is appropriate to choose losartan as
a positive control rather than placebo. Though Losartan
may improve outcomes of CKD patients, more efficacious
treatments would still be desirable. Based on the concern
above, this study has been designed to compare the effect
of CM with the effects of losartan.
The conclusions that may be drawn from the results
of this trial are limited by the lack of long-term follow-
up and evaluation. However, when the trial ends, those
patients that have not reached the endpoints will be
admitted to our research-based clinic and continue the
optimized CM treatment. All patients will be followed
up until they reach the endpoint. Further findings of this
trial will be updated.
Conclusions
This study will be the first double blind RCT to compare
the clinical effect of BYF and losartan on eGFR. We will
assess the capacity of BYF to reduce the incidence of
endpoint events, improve clinical symptoms and quality
of life. The trial was carefully designed in collaboration
with investigators, clinicians, methodologists, and sta-
tisticians. It will be performed rigorously according to
ethical and scientific principles. The results of this trial
will help to provide evidence-based recommendations
for clinicians.
Trial status
The trial is currently ongoing; we expect patient recruit-
ment to be completed in 2015.
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